Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; and Jacob M. Sands, MD; discuss immune checkpoint inhibitor–based strategies in limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC), practical considerations for integrating novel agents such as tarlatamab and lurbinectedin, and the emerging role of antibody-drug conjugates in the treatment of ES-SCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe current evidence supporting the use of immunotherapy, targeted therapies, and chemotherapy in LS- and ES-SCLC
• Identify common and severe treatment-related adverse events associated with newer SCLC therapies and appropriate management strategies
• Interpret pivotal trial data and safety findings for novel therapies being evaluated for the treatment of SCLC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Chair:

Charles M. Rudin, MD, PhD

Deputy Director
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Daiichi Sankyo, Merck, Novartis; Grant/Research Funding: Daiichi Sankyo; Royalty or Patent Benefits: Licensing and royalty payments regarding therapeutic targeting of DLL3

Faculty:

Anne Chiang, MD, PhD, FASCO

Associate Professor
Section of Medical Oncology
Yale School of Medicine
Associate Cancer Center Director, Clinical Initiatives
Yale Cancer Center
New Haven, CT

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Janssen, Jazz, Merck, Zai Lab; Grant/Research Funding: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, Zai Lab

Jacob M. Sands, MD

Assistant Professor
Harvard Medical School
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Gilead, Jazz Pharmaceuticals, Medtronic, Merck, Novartis, Pfizer, Sanofi; Grant/Research Funding: Amgen, Harpoon, Novartis

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including answers to audience questions, go to https://www.gotoper.com/courses/cases-and-conversations-transforming-small-cell-lung-cancer-treatment-through-emerging-evidence-and-expert-insights.

Release Date

January 27, 2026

Expiration Date

January 27, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.